Vaxcyte (PCVX) Income towards Parent Company (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Income towards Parent Company data on file, last reported at -$319.2 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$319.2 million, down 115.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$975.3 million (down 89.53% YoY), and the FY2025 annual result was -$804.0 million, down 74.94% from the prior year.
• Income towards Parent Company slipped to -$319.2 million in Q1 2026 per PCVX's latest filing, from -$247.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$39.1 million in Q1 2022 and troughed at -$319.2 million in Q1 2026.
• A 5-year average of -$130.1 million and a median of -$111.9 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company sank 168.73% in 2022, then increased 29.81% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$79.9 million in 2022, then plunged by 124.05% to -$179.1 million in 2023, then advanced by 29.81% to -$125.7 million in 2024, then sank by 97.14% to -$247.8 million in 2025, then decreased by 28.81% to -$319.2 million in 2026.
• Business Quant data shows PCVX's Income towards Parent Company at -$319.2 million in Q1 2026, -$247.8 million in Q4 2025, and -$213.1 million in Q3 2025.